Arcutis Biotherapeutics, Inc. ARQT R2KR3KPHARMA
Company Overview
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Why Investors Should Care
Generates a return on equity of 15.9%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $376.07M (+91.3% YoY); net profit $-16.14M.
- Trailing 12 Months Year-on-year growth — revenue +59.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 59.30% |
Stock Price Performance
| 1 Year: | +52.91% |
| 6 Months: | -0.42% |
| 3 Months: | +12.58% |
| 1 Month: | -9.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.13 · Neutral
P/E of 108.64 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 108.6.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARQT Arcutis Biotherapeutics, Inc. R2KR3KPHARMA | 23.90 | 108.64 | $3.00B | 0.00% | -4.03% | 15.86% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 2.78M | 5.19M | 38.11M | 49.57M | 30.86M | 44.76M | 65.85M | 81.50M | 99.22M | 129.50M | 105.40M | 129.86M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.83M | 7.49M | 8.69M | 11.69M | 9.78M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 57.02M | 74.01M | 90.53M | 117.81M | 95.61M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 81.55M | 88.62M | 82.01M | 99.43M | 104.70M | - |
| Operating Income | -6.95M | -8.54M | -14.65M | - | -28.65M | -35.63M | -38.30M | - | -36.09M | -42.08M | -57.08M | -62.63M | -65.83M | -104.75M | -76.27M | -66.76M | -36.90M | -31.62M | -50.08M | -39.07M | -24.53M | -14.61M | 8.53M | 18.39M | -9.09M | 16.43M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.82M | -11.95M | 11.12M | 21.43M | -6.27M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.98M | 3.03M | 3.07M | 3.00M | 4.37M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -24.78M | -15.54M | 7.49M | 17.86M | -11.20M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 279.00K | 342.00K | 80.00K | 470.00K | 93.00K | - |
| Net Income | -6.66M | -8.29M | -14.48M | -12.57M | -28.01M | -35.41M | -38.20M | -34.05M | -36.04M | -42.01M | -56.98M | -64.32M | -67.41M | -107.71M | -80.10M | -70.99M | -44.77M | -35.38M | -52.33M | -41.54M | -25.06M | -15.89M | 7.41M | 17.39M | -11.29M | 15.01M |
| Diluted EPS | - | - | - | - | - | -0.94 | -1.01 | - | -0.76 | -0.84 | -1.14 | -1.27 | -1.31 | -1.89 | -1.31 | -1.16 | -0.73 | -0.32 | -0.42 | -0.33 | -0.20 | -0.13 | 0.06 | 0.13 | -0.09 | 0.11 |
| R&D Expense | 6.20M | 7.21M | 12.35M | - | 25.18M | 30.01M | 32.74M | - | 21.63M | 30.77M | 40.60M | 40.62M | 38.20M | 69.73M | 35.34M | 25.22M | 26.24M | 23.14M | 19.30M | 19.50M | 17.54M | 19.45M | 19.60M | - | 30.63M | 20.36M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | - | 3.69M | 59.61M | 196.54M | 376.07M |
| Cost of Revenue | - | - | - | - | 754.00K | 4.99M | 19.13M | 36.70M |
| Gross Profit | - | - | - | - | 2.93M | 54.62M | 177.41M | 339.38M |
| Operating Expenses | - | - | - | - | 304.56M | 295.72M | 305.81M | 351.60M |
| Operating Income | -19.73M | -43.13M | -136.65M | - | -301.63M | -241.10M | -128.40M | -12.23M |
| EBITDA | - | - | - | - | -294.87M | -228.56M | -110.27M | 1.78M |
| Interest Expense | - | - | - | - | 15.65M | 29.71M | 27.17M | 12.08M |
| Pretax Income | - | - | - | - | -311.46M | -259.03M | -139.39M | -14.97M |
| Tax Provision | - | - | - | - | 0 | 3.11M | 647.00K | 1.17M |
| Net Income | -19.25M | -42.00M | -135.68M | - | -311.46M | -262.14M | -140.04M | -16.14M |
| Diluted EPS | - | -22.78 | -3.80 | - | -5.66 | -3.78 | -1.16 | -0.13 |
| R&D Expense | 17.94M | 36.52M | 115.31M | 145.56M | 182.44M | 110.58M | 76.42M | 77.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 107.01M | 298.27M | - | 449.27M | 341.37M | 348.89M | 432.97M |
| Current Assets | - | - | - | - | - | 437.41M | 330.43M | 335.82M | 411.23M |
| Cash & Equivalents | - | - | 63.34M | 65.08M | - | 53.64M | 88.40M | 71.33M | 42.91M |
| Inventory | - | - | - | - | - | 7.51M | 13.13M | 14.53M | 22.63M |
| Receivables | - | - | - | - | - | 8.46M | 25.81M | 73.07M | 146.23M |
| Total Liabilities | - | - | 5.55M | 27.65M | - | 239.69M | 252.70M | 191.35M | 243.49M |
| Current Liabilities | - | - | 5.24M | 22.60M | - | 37.81M | 46.67M | 81.01M | 129.84M |
| Long Term Debt | - | - | - | 0 | - | 197.77M | 201.80M | 107.20M | 107.96M |
| Total Debt | - | - | - | - | - | 202.54M | 205.92M | 109.77M | 114.22M |
| Total Equity | -4.99M | -23.99M | -65.03M | 270.62M | - | 209.58M | 88.67M | 157.54M | 189.48M |
| Shares Outstanding | - | - | - | - | - | 61.04M | 96.79M | 117.85M | 123.33M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.09M | -42.84M | -113.03M | - | -257.71M | -247.06M | -112.16M | -5.62M |
| Investing Cash Flow | -11.53M | -26.32M | -181.82M | - | -87.20M | 180.23M | 28.82M | -30.25M |
| Financing Cash Flow | 61.59M | 93.10M | 298.14M | - | 301.80M | 101.32M | 66.20M | 6.97M |
| Capital Expenditure | -0 | -295.00K | -321.00K | - | -23.28M | -428.00K | -5.14M | -10.69M |
| Free Cash Flow | -14.09M | -43.13M | -113.35M | - | -281.00M | -247.49M | -117.30M | -16.31M |
| Net Change in Cash | - | - | - | - | -43.12M | 34.50M | -17.14M | -28.91M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 79.5% | 91.6% | 90.3% | 90.2% |
| Operating Margin % | - | - | - | - | -8,183.0% | -404.5% | -65.3% | -3.3% |
| Net Margin % | - | - | - | - | -8,449.8% | -439.8% | -71.3% | -4.3% |
| ROE % | 80.3% | 64.6% | -50.1% | - | -148.6% | -295.6% | -88.9% | -8.5% |
| ROCE % | - | -42.4% | -49.6% | - | -73.3% | -81.8% | -47.9% | -4.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Montanova Capital LLC | 9.89% | 12.44M | $295.75M |
| 2 | Blackrock Inc. | 8.39% | 10.55M | $250.77M |
| 3 | Frazier Life Sciences Management, L.P. | 7.86% | 9.87M | $234.82M |
| 4 | Rubric Capital Management LP | 6.58% | 8.27M | $196.70M |
| 5 | Polar Capital Holdings PLC | 5.26% | 6.61M | $157.11M |
| 6 | State Street Corporation | 4.63% | 5.82M | $138.47M |
| 7 | Vanguard Capital Management LLC | 3.97% | 4.99M | $118.63M |
| 8 | Morgan Stanley | 3.54% | 4.45M | $105.85M |
| 9 | Jennison Associates LLC | 3.36% | 4.22M | $100.33M |
| 10 | Shaw D.E. & Co., Inc. | 3.14% | 3.95M | $93.92M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARQT
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving Fundamentals - ChartMill
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPek96MzYtQUIzNExTQnVLR21yY3hNWThVTnhYREJGczdhVmZidk9pRU1EU1dHQXFKSUNTVVRQU2NwSUZIRWpBWk9wOUFtekJCS0NhUEZEYVdXMkYxNzF1VDFFTnpETE90U2M2ODJKOG5HS2tRUUlhdDd3X2N5cEczb0JUNWZTSkFkREVZZU…
Here's Why You Should Add ARQT Stock to Your Portfolio Now - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOSTJfNF9yZll1cnhlTl9lTGMtcUJRbEJiNnNVcllXSGhjWXlGUnRSeml1VmduWkt2VUQ2LXRoVHBxb3dnelBZbnN0Z21neUVoMDEtS2RpdDVwV1AwNXNmSks4dHllYUQ0OG82Y014X251YzJMaWFiZXJvMzhTQnBZV284UzJyUzJ4ZktucF…
Is Arcutis Biotherapeutics (ARQT) Stock Too Rich To Stay Reasonable? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxQcGhIWjRGc0ZJWVhQVnFzTV9rUWx1cjBrdU1oZEpuMFNlUU9GVWtWMzZySWo0WUIySC01ZFRJNzZKU3lhUEtMZmV6ZjZpa0ZEOEdLM2FGUGkxUzVwSWN4LUhyQkJPdUlMV1FXTFpscmhiY2R1NDlZTmQ2UzFMME5CdVA5am5CNExOMTNLNj…
(ARQT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQdzZOVjJxcDhvYnRVbXRSdU5OM3VJcVZlR2hkY3NyRGpKUEdwMlAwN1pPelRuZlptMWxTLWFjS3A2Z1YxUHpscE5hZ1FfMFljODlWc0thQUxrLW5waFhtdEgzUlRwOElYZDVjLWRobEpCbm1yakUtcVNJT0dJYjdXcW44UUdqSTdYejNrOD…
Arcutis Biotherapeutics (ARQT) Stock Trades At A Discount To Sales But Fair Value Looks Tight - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQSk10amNxaTJmcXZieldvd0VueUdsaGlhRWxrYnpyMEhhZ2dFUHFBbjhqNjNxWTh2WGt3X3J4OEhvb0txbnVqcl9aQjJkVUlyY1VVSWJtQ3BlZTRKOWphUDNCZEVHODN0QzR4NVZOcThBdDRPQVYyQkhzYUlUZWxrdVNBcHUtQVlkSVlnX3…
Arcutis (NASDAQ: ARQT) insider plans $956K share sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQUzBaaGFBSkVPOEZ5UDBSYWVyeEMtUFlPOHdSQXlsRlVSemdZOWZ6Vi1SNU9ELV9fLW1Na3h4ODJzNTU0SWVjUXNIVXNNTWZYQ3RDWU8zTGFZa0U4TU1jdFZhR2hmeHdxU2E3NGdfTDdVLUNlc2EyaUhxeENyZm0xb21NamZEVF91MEpoYi…
ARQT — Frequently Asked Questions
What is the current share price of Arcutis Biotherapeutics, Inc. (ARQT)?
As of 2026-09-07 16:24 PDT, Arcutis Biotherapeutics, Inc. (ARQT) trades at $23.90 on NasdaqGS. Its 52-week range is $15.32 to $31.20.
What is the market capitalisation of ARQT?
Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalisation of $3.00B on NasdaqGS.
What is the P/E ratio of ARQT?
ARQT trades at a trailing price-to-earnings (P/E) ratio of 108.64. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 16.67.
What is the return on equity (ROE) of ARQT?
ARQT has a return on equity (ROE) of 15.86%. Its return on capital employed (ROCE) is -4.03%.
Is ARQT a good stock to buy?
This page provides a data-driven analysis of Arcutis Biotherapeutics, Inc. (ARQT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.